3 activation domain. The SREBP-1c isoform is a much weaker activator of gene expression because it lacks 29 acidic rich amino acids present in 1a. Using a nuclease mapping technique to evaluate the relative levels of SREBP-1a and SREBP-1c mRNA, the ratio was shown to vary in different tissues of the body over a ~50-100 fold range. In liver and adipose, 1c mRNA is 9 and 3 fold more abundant than SREBP-1a respectively whereas in spleen SREBP-1a is 10 times more abundant than 1c (8) . Whether these ratios reflect similar differences in the levels of each protein remains to be firmly established. In all cultured cell lines examined SREBP-1a was expressed at higher levels (8) . 1c mRNA is the predominant isoform in adult liver and adipose so it is likely to be the key protein involved in SREBP-1 dependent processes in these tissues. Why different tissues express different ratios of SREBP-1a and -1c is not clear.
It is possible that the more active 1a isoform is preferentially expressed when there is a high demand for cholesterol and fatty acids such as when new membrane is required during periods of rapid cell division.
SREBP-1a stimulates gene expression
in vitro and in cultured cells by interacting with the transcriptional coactivators CBP and P300 (10, 11; and Fig. 1) . These are large ubiquitous transcriptional coactivator proteins that are recruited to specific promoters through binding to activation domains of several DNA binding transcription factors in addition to SREBPs (12) . The shorter activation domain of SREBP-1c does not interact efficiently with CBP or P300 and how this isoform activates transcription is not clearly understood 2 . The single SREBP-2 isoform also interacts with CBP and P300 to activate transcription ( Fig. 1) . The N-terminal domain of SREBP-1a also interacts with a separate multi-subunit complex alternately called vitamin D receptor interacting protein (DRIP) or activator recruited cofactor (ARC) (13) . This heterogeneous complex increases transcription through interacting with activation domains of several other DNA binding transcriptional regulatory proteins in addition to SREBP-1a. The DRIP/ARC interaction is independent of CBP/P300.
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As members of the bHLHLZ family of DNA binding proteins, SREBPs form dimers that recognize the inverted repeat E-box 5'-CANNTG-3' (where N represents any base). bHLH sub-families can be classified according to their preference for specific bases at the middle positions of the E-box (14) .
SREBPs belong to the same sub-family as Myc/Max and USF which all prefer the 5'-CACGTG-3' E-box.
However, SREBPs are further distinguished because they not only bind to this inverted repeat but also to the direct repeat sterol regulatory element (SRE) 5'-TCACNCCAC-3' or to related sites (15). This flexibility is due to a unique tyrosine residue in the SREBP basic domain that corresponds to an arginine in all other E-box binding bHLH proteins. Kim et al (16) demonstrated the importance of the tyrosine residue by changing it to an arginine in order to mimic other bHLH proteins. The resulting protein bound only to E-boxes. The reciprocal mutation changing the arginine of the related USF1 protein to a tyrosine converted it into an E-box and SRE recognizing protein. When the X-ray structure of the DNA binding domain of SREBP-1 bound to the SRE element was compared to DNA bound structures for other bHLH proteins it was revealed that the tyrosine allows the basic domain to adopt a slightly different conformation allowing it to specifically recognize the direct repeat site (17) .
This duality in DNA recognition has significant functional implications because all cholesterol regulated SREBP dependent-promoters that have been carefully evaluated contain direct repeat SRE type sites and not E-boxes (18) may be selectively involved in activation of genes involved in fatty acid metabolism and de novo lipogenesis whereas SREBP-2 may be more selective for genes involved directly in cholesterol homeostasis (22, 24) . Moreover, aberrant expression of SREBPs in mice result in metabolic syndromes with physiologic effects similar to specific disorders of lipid metabolism in humans (28) . Also, overexpression of SREBP-1 and -2 have been documented in livers and adipose tissue of the leptin deficient ob/ob mouse or obese Zucker Rat respectively (29, 30) .
Addition of excess cholesterol resulted in the inhibition of processing for membrane bound precursor forms of both SREBPs -1 and -2 in experiments performed in both animals (31) and cultured cells (32) .
However, when hamsters were fed a diet supplemented with a bile acid binding resin and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor to short-circuit liver cholesterol regulation and setup a pseudo-low cholesterol environment, both expression and proteolytic activation of SREBP-2 were increased (33) . In contrast, expression of SREBP-1 was not altered nor was processing of membrane bound SREBP-1 accelerated in these animals. In fact, SREBP-1 processing was inhibited (33) .
Over-expression of SREBP-1a in cultured cells or animal livers resulted in activation of genes of cholesterol and fatty acid metabolism (20). Interestingly, in the animal studies this was associated with an increase in hepatic levels of cholesterol and triglycerides but serum levels were largely unaffected.
Crossing these animals to LDL receptor knockout animals resulted in a dramatic increase in circulating levels of cholesterol and triglycerides (34) . Thus, lack of accumulation of serum lipids in the SREBP-1a
over-expressing strain was likely due to unregulated expression of hepatic LDL receptors mediated by the over-expression of SREBP-1a.
Similar over-expression of SREBP-2 resulted in accumulation of both lipid classes as well. However, there was more cholesterol relative to fatty acids in both cultured cells and livers relative to SREBP-1a over-expressors (22, 24) . Because the activation potential for SREBP-1c is significantly lower than either SREBP-1a or SREBP-2 (9), its over-expression in liver resulted in a much lower level of activation for genes of both fatty acid and cholesterol metabolism and a correspondingly lower level of accumulation of fatty acids and cholesterol (22, 24, 34) . 7 triglycerides; symptoms reminiscent of the human disorder congenital generalized lipodystrophy. Two follow up studies further support a key role for SREBP-1c in insulin action. In one report it was noted that these same lipodystrophic animals also had very low levels of serum leptin and that leptin administration resulted in a reversal of the insulin resistance (36) . In a related report, it was demonstrated SREBP-1c mRNA levels decreased in rats treated with streptozotocin to induce diabetes and insulin administration reversed this effect (37) .
Feeding a high carbohydrate diet to rodents after a period of fasting results in a significant activation of the entire lipogenic program which is a signature insulin response (38) . SREBP-1c mRNA expression was activated during this fasting/refeeding regimen in normal animals (23, 25) . Also, over-expression of SREBP-1c in liver prevented the down regulation of lipogenic genes during fasting (23) . Additionally, re-activation of the hepatic lipogenic program during the feeding phase was not observed in animals where the SREBP-1 gene was disrupted even though the SREBP-2 gene was expressed at normal levels (27) . These studies provide compelling evidence that SREBP-1c is a key transcriptional activator for early events in the activation of lipogenesis. Interestingly, the SREBP-1 gene in these knockout animals produces a truncated mutant mRNA, which was still induced normally during the refeeding stage (27) .
The ubiquitous bHLHLZ proteins USF1 and USF2 have been proposed to be involved in the fasting/refeeding response since fatty acid synthase mRNA was expressed at reduced levels during the refeeding phase in animals where either USF1 or USF2 genes were inactivated by homologous recombination (39) . Exactly how SREBP-1c and USF proteins might both be involved in the fasting and refeeding response is unknown at present but it is possible that USF functions as a SREBP-1 co-regulator similar to Sp1 in the LDL receptor promoter (40) . SREBP-1 is a more likely primary target of insulin because it is subject to multiple levels of regulation by hormones and nutritients that affect fuel homeostasis whereas USF levels are largely unchanged by these same manipulations (27) . 
Regulation of SREBPs by Fatty Acids
Because SREBPs are regulated directly by cholesterol and they are involved in both cholesterol and fatty acid metabolism, it was important to determine if they are directly regulated by fatty acids as well. The addition of oleic acid and other longer chain unsaturated fatty acids inhibited sterol regulatory element mediated transcription and decreased processing of membrane bound SREBP-1 and SREBP-2 in cultured cells (44, 45) . A series of reports followed that evaluated SREBP regulation by different types of fatty acids in animal feeding studies. Three studies reported SREBP-1 mRNA expression was significantly suppressed when diets were supplemented with specific polyunsaturated fatty acids (PUFA) or fish oil (46) (47) (48) . One of these studies provided further evidence that SREBP-1 mRNA stability was decreased in livers of PUFA fed animals (46) . In a separate animal study SREBP-1 mRNA was only slightly affected but the level of processed SREBP-1 protein was significantly reduced when PUFA were added to the diet (49) . SREBP-2 processing in these studies was not altered. There were significant differences in feeding regimens, dietary composition (other than the fatty acid), and choice of animal model that are likely to account for differences reported in these separate studies. Therefore, it is likely that SREBP-1 mRNA levels and protein processing are both affected by fatty acids.
Since their identification as bHLHLZ transcriptional regulatory proteins in 1993, the SREBPs have been shown to possess highly unique functional characteristics that define them as key regulators of nutritional homeostasis. There is compelling evidence of a key role for coordinate regulation of fatty acid and cholesterol metabolism through SREBP proteins (Fig. 2) . SREBP-1c gene expression and protein promoter (19; and references therein). Additionally, the requirement for specific co-regulators in the same promoter can be distinct depending on the individual SREBP isoform that is activating gene expression (19) . Thus, future studies that unravel the complexities in the SREBP system will provide significant insights into mechanisms of both gene regulation and nutritional homeostasis. 
